John Tilmon, PA
Physician Assistant · Sterlington, LANPI 1619903721
Payments from drug & device makers
Across 155 payments — averaging $19.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$893
- Bayer$458
- Otsuka America Pharmaceutical, Inc.$299
- Novo Nordisk$239
- Boehringer Ingelheim$164
- Lilly USA, LLC$141
- plus $787 from 17 others
What the payments were for
- Food & beverage$2,92698%
- Education$562%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 53 | $893 |
| Bayer | 23 | $458 |
| Otsuka America Pharmaceutical, Inc. | 8 | $299 |
| Novo Nordisk | 14 | $239 |
| Boehringer Ingelheim | 9 | $164 |
| Lilly USA, LLC | 9 | $141 |
| AstraZeneca | 5 | $122 |
| Ardelyx, Inc. | 1 | $114 |
| Abbott | 7 | $100 |
| Astellas Pharma US Inc | 5 | $87 |
| Pfizer | 4 | $57 |
| Teva Pharmaceuticals USA, Inc. | 2 | $51 |
| Avanir Pharmaceuticals, Inc. | 3 | $49 |
| Neurocrine Biosciences, Inc. | 2 | $46 |
| Exact Sciences | 2 | $35 |
| Lundbeck LLC | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Smith+Nephew | 1 | $15 |
| Amgen | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| GSK | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,982 in reported general payments places this provider in the 85th percentile of 1,246 physician assistant providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 169 | $130,617 |
| OzempicSemaglutide | 88 | $86,381 |
| TradjentaLinagliptin | 63 | $46,108 |
| MounjaroTirzepatide | 28 | $29,247 |
| JanuviaSitagliptin Phosphate | 25 | $28,206 |
| EliquisApixaban | 35 | $27,953 |
| FarxigaDapagliflozin Propanediol | 23 | $22,986 |
| LinzessLinaclotide | 27 | $19,837 |
| KerendiaFinerenone | 11 | $11,491 |
| TrulicityDulaglutide | 11 | $10,717 |
| SynjardyEmpagliflozin/Metformin Hcl | 13 | $9,553 |
| PremarinEstrogens, Conjugated | 14 | $4,792 |
| Novolog FlexpenInsulin Aspart | 13 | $2,823 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $2,166 |
| FenofibrateFenofibrate Nanocrystallized | 59 | $2,055 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $164 | $186,278245 claims |
| Novo NordiskOzempic | $239 | $86,38188 claims |
| Lilly USA, LLCMounjaro, Trulicity | $141 | $39,96439 claims |
| PfizerEliquis, Premarin | $57 | $32,74449 claims |
| AstraZenecaFarxiga | $122 | $22,98623 claims |
| AbbVieLinzess | $893 | $19,83727 claims |
| BayerKerendia | $458 | $11,49111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,246 physician assistant providers in Louisiana.
Other physician assistant in Sterlington
- Shelly EsnardBaton Rouge$141K
- Jefferson OberleNew Orleans$66K
- Jennifer ScheuermannNew Orleans$56K
- Claire DarreJefferson$50K
- Elizabeth ClementNew Orleans$35K
- Mary Negrotto GuntherSlidell$29K
- Kristen HebertZachary$27K
- David GsellNew Orleans$26K
- Nakia BrooksNew Orleans$25K
- Savannah SanchezBaton Rouge$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.